2016
Changes in quality of life after radiation therapy for localized prostate cancer after dissemination of intensity modulated radiation therapy
Wang E, Wang S, Soulos P, Chen R, Kim S, Gross C, Yu J. Changes in quality of life after radiation therapy for localized prostate cancer after dissemination of intensity modulated radiation therapy. Journal Of Radiation Oncology 2016, 6: 295-300. DOI: 10.1007/s13566-016-0269-0.Peer-Reviewed Original ResearchExternal beam radiation therapyIntensity-modulated radiation therapyMental component scoreRadiation therapyProstate cancerEnd Results-Medicare Health Outcomes SurveyEra of IMRTComponent scoresImproved health-related qualityNonmetastatic prostate cancerPhysical component scoreHealth-related qualityHealth Outcomes SurveyStandard of careProstate cancer patientsExternal beam radiotherapyBeam radiation therapyQuality of lifeMethodsThe SurveillanceElderly patientsHRQOL measurementCancer patientsOutcome SurveyBeam radiotherapyLater era
2015
Myelodysplastic Syndromes and Acute Myeloid Leukemia in Prostate Cancer Patients after Radiotherapy, a Population-Based Study
Wang R, Zeidan A, Soulos P, Yu J, Davidoff A, Gore S, Gross C, Ma X. Myelodysplastic Syndromes and Acute Myeloid Leukemia in Prostate Cancer Patients after Radiotherapy, a Population-Based Study. Blood 2015, 126: 3295. DOI: 10.1182/blood.v126.23.3295.3295.Peer-Reviewed Original ResearchMDS/AMLProstate cancer patientsIntensity-modulated radiotherapyProstate cancer diagnosisImpact of radiotherapyCancer patientsMyelodysplastic syndromeProstate cancerMyeloid malignanciesSecond malignanciesHazard ratioCancer diagnosisRadiation modalitiesEnd Results-Medicare databaseElderly prostate cancer patientsRisk of MDSMultivariate modelRetrospective cohort studyRole of radiotherapyElixhauser comorbidity scoreAcute myeloid leukemia diagnosisHistory of anemiaAcute myeloid leukemiaEnd of studyExternal beam radiotherapy80 SUBSEQUENT MYELODYSPLASTIC SYNDROMES IN PROSTATE CANCER PATIENTS AFTER RADIOTHERAPY, A POPULATION-BASED STUDY
Wane R, Zeidan A, Soulos P, Yu J, Davidoff A, Gore S, Gross C, Ma X. 80 SUBSEQUENT MYELODYSPLASTIC SYNDROMES IN PROSTATE CANCER PATIENTS AFTER RADIOTHERAPY, A POPULATION-BASED STUDY. Leukemia Research 2015, 39: s39. DOI: 10.1016/s0145-2126(15)30081-3.Peer-Reviewed Original Research
2013
The Dissemination of New Technologies and Temporal Trends in Curative Therapy for Prostate Cancer Patients With Low Likelihood of Clinical Benefit
Raldow A, Presley C, Yu J, Cramer L, Soulos P, Long J, Makarov D, Gross C. The Dissemination of New Technologies and Temporal Trends in Curative Therapy for Prostate Cancer Patients With Low Likelihood of Clinical Benefit. International Journal Of Radiation Oncology • Biology • Physics 2013, 87: s177-s178. DOI: 10.1016/j.ijrobp.2013.06.459.Peer-Reviewed Original ResearchProstate cancer patientsCurative therapyClinical benefitCancer patientsLower likelihoodTemporal trendsPatientsTherapy
2012
Proton radiotherapy for prostate cancer in the Medicare population: Patterns of care and comparison of early toxicity with IMRT.
Yu J, Soulos P, Cramer L, Roberts K, Herrin J, Potosky A, Gross C. Proton radiotherapy for prostate cancer in the Medicare population: Patterns of care and comparison of early toxicity with IMRT. Journal Of Clinical Oncology 2012, 30: 4651-4651. DOI: 10.1200/jco.2012.30.15_suppl.4651.Peer-Reviewed Original ResearchProstate cancer patientsSix monthsShort-term toxicityOne-yearCancer patientsPRT patientsProstate cancerProton radiotherapyLogistic regressionTreatment-related complicationsOne-year outcomesCumulative complication rateMultivariable logistic regressionPatient-reported outcomesPatterns of careConditional logistic regressionHigher socioeconomic statusGU complicationsGU toxicityComplication rateEarly toxicityDiagnosis codesLong-term effectsRadiation therapyMedicare populationThe influence of physician densities and patient characteristics on the decision to treat prostate cancer patients with varying clinical benefit.
Yu J, Aneja S, Makarov D, Roberts K, Gross C. The influence of physician densities and patient characteristics on the decision to treat prostate cancer patients with varying clinical benefit. Journal Of Clinical Oncology 2012, 30: 19-19. DOI: 10.1200/jco.2012.30.5_suppl.19.Peer-Reviewed Original ResearchHealth system factorsHealth service areasCurative therapyUrologist densityClinical benefitProstate cancerRadiation oncologistsPhysician densitySystem factorsRadiation oncologist densityEnd Results (SEER) databaseLower likelihoodReceipt of treatmentMarital statusProstate cancer patientsHigher likelihoodLogistic regression modelsArea Resource FilePatient characteristicsPatient factorsInitial treatmentResults databasePatient populationCancer patientsProper therapy
2011
The Influence of Physician Densities and Patient Characteristics on the Decision to Treat Prostate Cancer Patients with Varying Clinical Benefit
Aneja S, Makarov D, Gross C, Roberts K, Yu J. The Influence of Physician Densities and Patient Characteristics on the Decision to Treat Prostate Cancer Patients with Varying Clinical Benefit. International Journal Of Radiation Oncology • Biology • Physics 2011, 81: s553. DOI: 10.1016/j.ijrobp.2011.06.871.Peer-Reviewed Original ResearchProstate cancer patientsPatient characteristicsClinical benefitCancer patientsPhysician densityPatients
2010
Assessing cardiac risk using heart rate variability in a phase II study of androgen-deprivation therapy and bevacizumab in noncastrate metastatic prostate cancer patients.
Gibney G, Elfiky A, Hoimes C, Burns A, Rowen E, McDonough J, Lampert R, Gross C, Kelly W. Assessing cardiac risk using heart rate variability in a phase II study of androgen-deprivation therapy and bevacizumab in noncastrate metastatic prostate cancer patients. Journal Of Clinical Oncology 2010, 28: tps244-tps244. DOI: 10.1200/jco.2010.28.15_suppl.tps244.Peer-Reviewed Original Research